Franc Gay, MD, PhD, of the Universy of Tur, Tur, Italy, briefly scrib the major differenc the clil prentatn of plasma cell lkemia (PCL) and multiple myeloma (MM), cludg age, severy and risk of chromosomal abnormali, spe both beg plasma cell neoplasms. Dr Gay go on to discs the optns for management of PLC, highlightg that although there has been a recent crease survival rate is still suboptimal due to further plitns and fectns. Addnally, Dr Gay scrib the therapy regimen optns for patients eligible for transplantatn and the alternative multi-agent chemotherapy optns for those who are not eligible. This terview took place at the Controversi Multiple Myeloma (COMy) 2019 World Congrs Paris, France.
Contents:
- FRANC GAY
- FRANC GAY, MD, PHD
- FRANC GAY, MD, ON THE FORTE TRIAL: TRIPLET THERAPY FOR NEWLY DIAGNOSED MULTIPLE MYELOMA
- GAY MOSW MOSW CY GUI
- FIRG OF GAY CATHOLIC SCHOOL TEACHER ULD TT LATT SUPREME COURT LG
FRANC GAY
Franc Gay speaks exclively to VJHemOnc on Treatg myeloma and associated disorrs. Watch terviews and discsns wh Franc Gay here. * francesca gay md *
Franc Gay is Associate Profsor the Universy of Toro, Department of Molecular Btechnology and Health Scienc, and works as hematologist at the SSD Clil trials on-ematology and multiple myeloma, Divisn of Hematology, Azienda Ospedaliero-Universaria Ctà lla Salute e lla Scienza di Toro, Italy. Gay’s ma rearch foc on the diagnosis and the clil and experimental treatment of patients wh multiple myeloma and associated disorrs, particularly of newly diagnosed patients eligible for tologo stem-cell transplantatn.
FRANC GAY, MD, PHD
Franc Gay, MD, PhD, discs the FORTE trial parg rfilzomib pl lenalidomi and xamethasone vers rfilzomib pl cyclophosphami and xamethasone newly diagnosed patients wh multiple myeloma. * francesca gay md *
Franc Gay, MD, PhD, is currently an Associate Profsor of Hematology at the Myeloma Un the Divisn of Hematology at the Universy of Tur, Tur, Italy, havg prevly worked as a Hematologist at the Azienda Ospedaliera Ctà lla Salute e lla Scienza di Toro, Tur, Italy. Dr Gay pleted her medil gree 2004 and her fellowship hematology 2008, both om the Universy of Tur.
In 2014, Dr Gay obtaed a PhD Medice and Experimental Therapy and has been a member of the young European Myeloma Network (EMN) board sce s formatn 2019. Dr Gay’s rearch is foced on the treatment of multiple myeloma and s associated diseas.
FRANC GAY, MD, ON THE FORTE TRIAL: TRIPLET THERAPY FOR NEWLY DIAGNOSED MULTIPLE MYELOMA
Franc Gay, MD, PhD, discs nsolidatn as a standard of re the transplant settg * francesca gay md *
Dr Gay has prevly worked on many cuttg-edge clil trials and is currently heavily volved rearch vtigatg prognostic factors, such as measurable ridual disease (MRD), multiple myeloma. Gay et al.
FigureDisclosurGay:Amgen: Honoraria, Membership on an enty's Board of Directors or advisory mte; Takeda: Honoraria, Membership on an enty's Board of Directors or advisory mte; Bristol-Myers Squibb: Honoraria, Membership on an enty's Board of Directors or advisory mte; Roche: Membership on an enty's Board of Directors or advisory mte; GSK: Membership on an enty's Board of Directors or advisory mte; AbbVie: Membership on an enty's Board of Directors or advisory mte; Adaptive: Membership on an enty's Board of Directors or advisory mte; Seattle Geics: Membership on an enty's Board of Directors or advisory mte; Onpeptis: Membership on an enty's Board of Directors or advisory mte; Janssen: Honoraria, Membership on an enty's Board of Directors or advisory mte; Celgene: Honoraria, Membership on an enty's Board of Directors or advisory mte. Franc Gay, MD,. Franc Gay, Chiara Cerrato, Delia Rota Slabri, Moni Galli, Angelo Belotti, Elena Zamagni, Anton Ledda, Mariella Grasso, Emanuele Angelucci, Anna Mara Liberati, Patrizia Tosi, Franc Pisani, Stefano Spada, Ombretta Annibali, Anna Baraldi, Paola Omedé, Piero Galieni, Ra Rizzi, Norbert Psta, Sonia Ronni, Donatella Vcelli, Anna Maria Cao, Massimo Offidani, Anton Palumbo, Pellegro Mto, Michele Cavo, Mar Bocdoro; Carfilzomib-Lenalidomi-Dexamethasone (KRd) Inductn-Autologo Transplant (ASCT)-Krd Consolidatn Vs KRd 12 Cycl Vs Carfilzomib-Cyclophosphami-Dexamethasone (KCd) Inductn-ASCT-KCd Consolidatn: Analysis of the Randomized Forte Trial Newly Diagnosed Multiple Myeloma (NDMM).
GAY MOSW MOSW CY GUI
Explore gay Mosw wh Mr Hudson. The bt of Mosw for the discerng gay man. Where to sleep, eat, drk, shop and play. * francesca gay md *
June 28th 2018Franc Gay, MD, PhD, hematologist, Myeloma Un, Divisn of Hematology, Azienda Ospedaliero Universaria Ctà lla Salute e lla Scienza, discs the updated efficy data om the FORTE trial of patients wh newly-diagnosed multiple myeloma. Pieter Sonneveld, Meral Beksac, Bronno Van Der Holt, Melets A Dimopoulos, Angelo Michele Carella, Hez Ludwig, Sonja Zweegman, Thilo Zanr, Ruth Wter, Roman Hajek, Lucia Pantani, Lu Dozza, Franc Gay, Anna Maria Cao, Lu De Rosa, Franc Froni, Ulf-Henrik Mellqvist, Rossella Troia, Niels Frost Anrsen, Ka Lung Wu, Christoph Drisen, Sana Carvalho, Alexandra J.
FIRG OF GAY CATHOLIC SCHOOL TEACHER ULD TT LATT SUPREME COURT LG
Gay:GSK: Membership on an enty's Board of Directors or advisory mte; Adaptive: Membership on an enty's Board of Directors or advisory mte; AbbVie: Membership on an enty's Board of Directors or advisory mte; Roche: Membership on an enty's Board of Directors or advisory mte; Bristol-Myers Squibb: Honoraria, Membership on an enty's Board of Directors or advisory mte; Seattle Geics: Membership on an enty's Board of Directors or advisory mte; Onpeptis: Membership on an enty's Board of Directors or advisory mte; Amgen: Honoraria, Membership on an enty's Board of Directors or advisory mte; Celgene: Honoraria, Membership on an enty's Board of Directors or advisory mte; Janssen: Honoraria, Membership on an enty's Board of Directors or advisory mte; Takeda: Honoraria, Membership on an enty's Board of Directors or advisory mte.
Franc Gay, MD, of GIMEMA, European Myeloma Network, discs the potential role of rfilzomib/lenalidomi/xamethasone wh or whout transplantatn ducg high-qualy rpons, achievg negative mimal ridual disease, and rcg the risk of early relapse. Franc Gay, MD, PhD, discs the FORTE trial parg rfilzomib pl lenalidomi and xamethasone vers rfilzomib pl cyclophosphami and xamethasone newly diagnosed patients wh multiple myeloma.